Suggestions
Eric Kelsic
Co Founder & CEO at Dyno Therapeutics
Eric Kelsic is the Founder and CEO of Dyno Therapeutics, a biotechnology company based in Cambridge, Massachusetts. Established in May 2018, Dyno Therapeutics focuses on leveraging artificial intelligence and machine learning to enhance gene therapy, particularly through the engineering of Adeno-associated Virus (AAV) capsids for more effective delivery systems.12
Educational Background
- California Institute of Technology (Caltech): Bachelor of Science in Physics (2002 - 2006)
- Harvard University: Doctor of Philosophy (PhD) in Systems Biology (2008 - 2015)
Professional Experience
- Dyno Therapeutics: Founder & CEO (May 2018 - Present)
- Wyss Institute for Biologically Inspired Engineering: Staff Scientist under George Church (July 2016 - December 2018)
- Harvard Medical School: Postdoctoral Research Fellow, also under George Church (February 2015 - July 2016)
- Harvard University: Graduate Student in Systems Biology (August 2008 - January 2015)
Notable Contributions
Kelsic has been instrumental in developing innovative approaches for gene therapy, utilizing high-throughput experimental methods and next-generation DNA technologies. His work aims to improve therapeutic outcomes for patients by refining the mechanisms through which genes are delivered to target cells.23
Additional Information
Kelsic has also held various research roles throughout his career, including positions at Caltech and the National Institute of Standards and Technology. His diverse background includes both scientific research and teaching, having worked as an English instructor at Nankai University in China.23
Highlights
Looking forward to speaking at the 4th Next Generation Gene Therapy Vectors Summit (June 12-14, Boston), focused on innovating gene therapy capsid and payload design. I will be presenting on Dyno’s latest breakthroughs enabling machine-guided design of AAV capsids for ocular and CNS indications. For more info see https://ter.li/oz9aqf or contact Nick Mayne, Program Director for the event.
Great turnout of AAViators representing Dyno Therapeutics at this year’s #ASGCT Annual Meeting. The #AAV field is growing and moving fast, but we’re focused on learning how to make better gene therapies to help patients. Happy to reconnect with so many friends and colleagues at the meeting, every year this is such an inspiring event for me.
